Coca-Cola Stock Is Crushing the Market This Year. Is It Time to Buy?

Coca-Cola reported 5% organic revenue growth year-over-year in both Q4 and FY2025, with comparable currency-neutral operating income up 13% y/y while GAAP operating income fell 32% due to a $960M non-cash BODYARMOR impairment and currency headwinds. FY2025 free cash flow (ex-Fairlife contingent payment) was $11.4B and management guides FCF to ~$12.2B (~7% y/y), with 4–5% organic revenue growth and 5–6% comparable currency-neutral EPS growth for 2026. Shares are up ~11% YTD, trade at ~26x P/E, and yield 2.7% with a ~67% payout ratio; strong cash generation and margin gains (North America margin hit 30%) support the bullish case but the premium valuation leaves limited room for execution or multiple risk.

Analysis

Coca‑Cola’s recent outperformance looks driven less by a one‑off beat and more by a structural swing in mix and channel economics that management has quietly engineered: higher‑margin SKUs, tighter SKU rationalization, and pricing that has migrated from broad across‑the‑board increases to targeted, elastic categories. That combination lifts concentrate economics and translates to outsized margin expansion at the corporate level, but it is also fragile — elasticity tests in lower‑income cohorts and retailer promotional pullbacks can reverse the gain quickly.

The BODYARMOR writedown is a useful canary for acquisition risk: it signals integration and valuation execution risk on brands bought for growth rather than margin. Expect management under the new CEO to face a tradeoff between conserving cash for buybacks/dividend support and pursuing bolt‑on premiumization that could reintroduce goodwill impairment risk; which path they choose will be the dominant value driver over the next 12–24 months.

Currency volatility and bottler economics are second‑order levers that can amplify short‑term earnings swings. Bottler margin pressure or FX re‑strengthening in key markets can produce earnings volatility materially larger than the core concentrate business would suggest. Practically, the stock now behaves like a high‑quality, cash‑rich consumer play with low product risk but non‑trivial governance/allocations risk — steady in normal cycles, vulnerable if capital allocation goes awry or multiples reprice.

Key Decisions for Investors

• Core tranche (12–36 months): Buy KO on any >10% pullback from present levels; size as a 3–5% portfolio position. Hedge 25–35% of the position with 12‑month OTM puts (protect downside while keeping dividend exposure). Risk/Reward: asymmetric — steady cash returns plus 15–25% upside if margin trends hold; protected downside to a capped loss if hedged.
• Relative pair (6–12 months): Go long KO / short equal dollar SPY to isolate company‑specific execution (rather than macro). This isolates beverage mix and capital allocation alpha; expect mean reversion toward outperformance if management sticks to margin discipline. Close if KO underperforms SPY by >8% over a rolling 30‑day window (signal of operational deterioration).
• Income enhancement (3–9 months): Buy KO shares and sell 3–6 month covered calls at a modestly OTM strike to monetize near‑term option premium while retaining upside pickup. Use proceeds to finance periodic put hedges after material M&A headlines. Ideal if you believe dividends + buybacks are prioritized but want to reduce carry.
• Event/contrarian short (12 months): If incoming CEO signals an aggressive M&A push within first 9 months, consider a tactical short/underweight — acquisition fatigue and repeat impairments represent the fastest path to multiple compression. Catalyst window: next two quarterly calls and first 100 days of new CEO; unwind if management explicitly commits to buybacks/dividend prioritization.